Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail

Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail

India Pharma Outlook Team | Saturday, 14 June 2025

 Bristol Myers
  • Sotyktu met all primary and secondary endpoints in Phase 3 trials
  • Efficacy sustained through Week 52 in the PsA-2 trial
  • Sotyktu offers an oral TYK2 inhibitor for long-term PsA care

Bristol Myers Squibb has announced promising results of its fundamental tests of phase 3 Poatyk PSA-1 and PSA-2, evaluating Sotyktu (decravacitinib) in adults with active psoriatic arthritis (PSA). Tests have shown that Sotyktu has significantly improved the symptoms of joint and skin compared to placebo, reaching all primary and secondary points. 

In the PSA-1 study, 54.2 percent of Sotyktu patients reached an ACR20-Indicating response, at least a 20 percent improvement in PSA-EM symptoms, compared to 34.1 percent. In week 16, patients also had significant progress in secondary measures, including PASI 75 (skin improvement), HAQ-DI (physical function), and MDA (disease control). 

Also Read: Gujarat Boosts Drug Testing with Rs. 8 Cr Upgrade to Rajkot Lab

Notably, the treatment maintained a favorable security profile, consistent with previous studies. No new security concerns were observed. Common side effects included upper respiratory tract infections and mild cases of simple herpes. PSA-2 study data further supported Sotyktu's sustained efficacy, with patients continuing to show significant clinical responses until week 52. Those who remained at Sotyktu maintained their ACR20 improvements, reinforcing their potential as a long-term treatment option. 

Sotyktu is a selective and oral inhibitor of Tyk2 and represents a new therapeutic approach to psoriatic, a chronic immune-mediated disease that affects joints and skin. These findings highlight the continuous investment of Bristol Myers Squibb in innovative treatments for inflammatory diseases and its commitment to meeting the unmet needs of patients in the autoimmune space. With strong effectiveness, a consistent safety profile, and a convenient oral dosage, Sotyktu positions itself as an attractive option for PSA management and offers a new patient care.

on the deck

Most Viewed

Related Articles


© 2025 India Pharma Outlook. All Rights Reserved.